Iodine-131 metaiodobenzylguanidine (131I-mIBG) treatment in relapsed/refractory neuroblastoma
Conclusion Despite multimodality therapy, high risk neuroblastoma had a propensity of treatment failure in terms of relapsed or refractory, with some objective responses after 131I-mIBG treatments. The declined or non-rising Curie score upon second post-treatment total body scan was an important predictor of survival and aided a decision whether or not to proceed with bone marrow transplantation.
Conclusions: This series represents the largest case series of recurrent/metastatic ENB treated with PRRT. Our experience suggests that PRRT is feasible and can be an effective option in patients with unresectable locally extensive or metastatic ENB. Careful patient selection based on symptoms, imaging phenotype, disease volume and prior interventions may be factors that contribute to better outcomes. Given the rarity of the condition, ideally multi-centre prospective trials of PRRT in ENB are required to objectively assess disease control, quality of life and survival.
Conclusions This review describes how leukocyte-heparanase can be a double-edged sword in tumor progression; it can enhance tumor immune surveillance and tumor cell clearance, but also promote tumor survival and growth. We also discuss the potential of using heparanase in leukocyte therapies against tumors, and the effects of heparanase inhibitors on tumor progression and immunity. We are just beginning to understand the influence of heparanase on a pro/anti-tumor immune response, and there are still many questions to answer. How do the pro/anti-tumorigenic effects of heparanase differ across different cancer types? Does...
We report 2 cases of intravenous immunoglobulin refractory ITP in children receiving chemotherapy for high-risk neuroblastoma. ITP was successfully treated with the thrombopoietin-receptor-agonist romiplostim, allowing safe and timely continuation of antineuroblastoma therapies in these high-risk patients.
Authors: Maria Chimeno J, Sebastià N, Torres-Espallardo I, Balaguer J, Candela-Juan C, Loaiza JL, Adria M, Ibanez-Rosello B, Cañete A, Martí-Bonmatí L, Montoro A Abstract Purpose The aims of this study were to estimate the whole-body absorbed-dose with the Dicentric Chromosome Assay (DCA) (biodosimetry) for 131I-metaiodobenzylguanidine (131I-mIBG) therapy for high-risk neuroblastoma, and to obtain an initial correlation with the physical dosimetry calculated as described by the Medical Internal Radiation Dosimetry formalism (MIRD). Together both objectives will aidobjectives will aid the...
CONCLUSIONS: Chemotherapy plus hu14.18K322A, cytokines and NK cells is feasible and resulted in clinically meaningful responses in patients with refractory/recurrent neuroblastoma. Further studies of this approach are warranted in patients with relapsed and newly-diagnosed neuroblastoma. PMID: 28939747 [PubMed - as supplied by publisher]
In this study, we retrospectively analyzed the bone marrow infiltration status and hematological parameters of 111 cases of neuroblastoma. Among the 111 cases, 62 (55.9%) exhibited marrow infiltration. Erythrocytopenia, anemia, and thrombocytopenia were significantly (p10% malignant cells. The evaluation of blood cell count parameters with receiver operating characteristic curves indicated that erythrocytopenia can substantially improve the accurate prediction of the risk of bone marrow involvement with a Youden index of 0.60. The sensitivity and specificity were 90% and 70%, respectively, which correspond to a cut-off val...
Conclusions: Trebananib was well tolerated in pediatric patients with recurrent or refractory solid or CNS tumors. RP2D is 30 mg/kg. PMID: 28751444 [PubMed - as supplied by publisher]
ConclusionThe combination of bortezomib and irinotecan was well tolerated by patients with relapsed/refractory NBL with favorable toxicity profile. It also showed modest but promising clinical activity and merits further testing in Phase II studies.
Conclusions: Ribociclib demonstrated acceptable safety and PK in pediatric patients. MTD (470 mg/m(2)) and RP2D (350 mg/m(2)) were equivalent to those in adults. Observations of prolonged SD support further investigation of ribociclib combined with other agents in neuroblastoma and MRT. Clin Cancer Res; 1-9. ©2017 AACR. PMID: 28432176 [PubMed - as supplied by publisher]
ConclusionsBIT was well tolerated, but the addition of bevacizumab did not improve response rates in resistant NB compared to historical data for IT.